DSED and VC defibrillation tied to higher survival compared to standard defibrillation in refractory VF: NEJM

The main result was staying alive until being released from the hospital. Secondary outcomes were the cessation of ventricular fibrillation, restoration of spontaneous circulation, and a positive neurologic outcome, defined as a modified Rankin scale score of 2 or lower (meaning no symptoms to mild disability) at hospital discharge.

Key findings of the trial:

• The DSED group had a higher rate of survival to hospital discharge than the standard group (30.4% vs. 13.3%; relative risk, 2.21; 95% confidence interval [CI], 1.33 to 3.67)
• the VC group had a higher rate of survival than the standard group (21.7% vs. 13.3%; relative risk, 1.71; 95% CI, 1.01 to 2.88).
• In comparison to standard defibrillation, DSED, but not VC defibrillation, was linked to a larger proportion of patients having a favorable neurologic outcome (relative risks, 2.21 [95% CI, 1.26 to 3.88] and 1.48 [95% CI, 0.81 to 2.71], respectively).
• Return of spontaneous circulation occurred in 46.4% against 26.5%, and ventricular fibrillation was terminated in 84% of the DSED group versus 67.6% of the conventional group (RR, 1.25). (RR, 1.72).
• In the VC group, recovery of spontaneous circulation happened in 35.4% of cases while ventricular fibrillation termination occurred in 79.9% of cases, yielding an RR of 1.18 compared to traditional defibrillation (RR, 1.39).

The investigators claimed that all patients with refractory ventricular fibrillation should certainly consider either double defibrillation or an alternative pad placement.

"To further understand the effects of DSED and VC defibrillation for refractory ventricular fibrillation, more investigation is required. This should include trials that are explicitly powered to compare the two methods and those that take post-resuscitation care into account," they continued.

The authors concluded that until then, "such protracted types of defibrillations are not ready for routine therapy, although they may be taken into consideration when no other therapeutic alternatives remain."

REFERENCE

Cheskes S, Verbeek PR, Drennan IR, McLeod SL, Turner L, Pinto R, Feldman M, Davis M, Vaillancourt C, Morrison LJ, Dorian P, Scales DC. Defibrillation Strategies for Refractory Ventricular Fibrillation. N Engl J Med. 2022 Nov 6. doi: 10.1056/NEJMoa2207304. Epub ahead of print. PMID: 36342151.